EGFR G796D mutation mediates resistance to osimertinib

Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). Despite impressive initial tumor responses, development o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Di, Hu, Min, Bai, Yu, Zhu, Xuehua, Lu, Xuesong, Wu, Chunyan, Wang, Jiying, Liu, Li, Wang, Zheng, Ni, Jian, Yang, Zhenfan, Xu, Jianfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564797/
https://www.ncbi.nlm.nih.gov/pubmed/28572531
http://dx.doi.org/10.18632/oncotarget.17913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564797/
https://www.ncbi.nlm.nih.gov/pubmed/28572531
http://dx.doi.org/10.18632/oncotarget.17913

Ejemplares similares